ACHS Welcomes New Members to the Herbal Medicine Program Advisory Council

ACHS adds new experts to its Herbal Medicine Program Advisory Council to guide curriculum, trends, and outcomes, ...

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for ...
Investing

Incyte at Guggenheim Conference: Strategic Focus on Innovation

On Monday, 10 November 2025, Incyte Corporation (NASDAQ:INCY) presented at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. The company outlined its strategic priorities, ...
Taiwan News

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oral ANAVEX ® 3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life ...
Seeking Alpha

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson ...
WDTN

CLINUVEL to advance novel pharmaceutical formulations in preclinical program

first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...